Foundational Genetics Concepts (FG)
1. Explain basic genetics concepts using appropriate nomenclature.
2. Recognize the combined impact of genetic, behavioral, social, and environmental factors in the manifestation of disease and drug response.
3. Identify drug- and disease-associated genetic variations that facilitate development of prevention, diagnostic, and treatment strategies.
4. Differentiate between the clinical diagnosis of disease informed by genetics and the identification of genetic predisposition to disease.
5. Assess differences in genetic testing technologies, including sequencing and genotyping.
6. Recognize the legal protections against discrimination based on genetic test results.

Clinical PGx (CP)
1. Identify pharmacogenomic test results that are relevant to a patient’s care.
2. Interpret pharmacogenomic test results, including translating genotype to phenotype to drug therapy recommendation.
3. Determine the impact of genetic variation on pharmacokinetics and/or pharmacodynamics.
4. Identify medication-related problems that may be related to genetic variability, even when a pharmacogenomic test has not been done.
5. Recognize disease implications of pharmacogenomic test results and refer the patient to a genetics-trained healthcare provider when necessary.
6. Use family history to assess predisposition to disease and drug response.
7. Assess the quality and source of existing pharmacogenomic test results.
8. Distinguish between actionable and non-actionable pharmacogenomic test results using high-quality, evidence-based pharmacogenomics databases and clinical guidelines.
9. Integrate pharmacogenomic test results with other clinical variables to optimize medication therapy.
10. Recommend pharmacogenomic testing when appropriate.
11. Consider the cost, cost-effectiveness, and reimbursement issues relevant to pharmacogenomic tests and services.
12. Implement a pharmacogenomics-guided care plan in collaboration with the patient, caregivers, and other health professionals.
13. Document pharmacogenomic test results in the electronic health record.
14. Follow-up and monitor a pharmacogenomics-guided care plan.
15. Collaborate as a member of an interprofessional clinical pharmacogenomics team.
16. Identify patient populations that may be most likely to benefit from pharmacogenomic testing.
17. Identify genetic variations that predispose patients to adverse drug reactions and modify therapy accordingly to mitigate the risk.
18. Recognize the differences in pharmacogenomic allele frequencies among ancestry groups to guide appropriate test selection and maximize the appropriate use of medications in a population.
19. Educate patients and professional colleagues on the benefits and limitations of pharmacogenomics to optimize drug therapy.
20. Use a culturally-sensitive approach that considers potential ethical concerns when counseling patients about pharmacogenomic test results.
21. Use evidence-based resources and pharmacogenomics information to advance patient care.
22. Oversee clinical pharmacogenomics operations.
23. Fulfill a medication order considering the clinical implications of pharmacogenomics.
24. Create a written plan for continuous professional development in clinical pharmacogenomics.